{
  "nctId": "NCT02903446",
  "briefTitle": "Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions",
  "officialTitle": "Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions in Gout: A Pilot Study",
  "protocolDocument": {
    "nctId": "NCT02903446",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2017-07-26",
    "uploadDate": "2021-04-13T11:26",
    "size": 419104,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02903446/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 20,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-02-01",
    "completionDate": "2020-03-01",
    "primaryCompletionDate": "2020-03-01",
    "firstSubmitDate": "2016-09-13",
    "firstPostDate": "2016-09-16"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Age 30 years or older and able to provide informed consent\n* Diagnosis of gout according to the American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria\n* Radiographic foot bone erosion attributable to gout and confirmed by a radiologist\n* Serum urate of ≤ 5 mg/dL (300 µmol/L) or less\\*\n\nExclusion Criteria:\n\n* Treatment with bisphosphonates in the preceding 2 years\n* Any prior treatment with denosumab\n* Women of childbearing potential, who are not currently using birth control, are pregnant, planning to become pregnant, or are breast-feeding\n* Men planning to conceive in the next 12 months\n* Unstable systemic medical condition\n* Uncontrolled hyperthyroidism\n* Uncontrolled hypothyroidism\n* History of Addison disease\n* History of osteomalacia\n* History of osteonecrosis of the jaw (ONJ)\n* History of atypical femur fracture\n* History of tooth extraction, jaw surgery, dental implants, or other dental surgery within the prior 6 months\n* History of anorexia nervosa, bulimia (by history or physical) or obvious malnutrition.\n* Invasive dental work planned in the next 2 years\n* History of Paget's disease of bone\n* Other bone diseases which affect bone metabolism\n* Vitamin D deficiency \\[25(OH) vitamin D level \\< 20 ng/mL (\\<49.9 nmol/L)\\]†\n* Hypercalcemia\n* Elevated transaminases ≥ 2.0 x upper limit of normal (ULN)\n* Elevated total bilirubin \\> 1.5x ULN\n* History of any solid organ or bone marrow transplant\n* Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell carcinoma)\n* Hypocalcemia\n* Poorly tolerant of ULT including allopurinol, febuxostat, or probenecid\n* Estimated glomerular filtration rate \\< 30 mL/minute/1.73 m\\^2\n* Current use of any biological therapy (eg. infliximab, etanercept, adalimumab, etc.)\n* Treatment history with pegloticase or another recombinant uricase\n* Recipient of an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "30 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "CT Bone Erosion Score",
        "description": "Change in the foot CT bone erosion score from baseline to 12 months. A total of 14 bones of the foot are scored. Each bone of the scored separately on a scale from 0 to 10, based on the proportion of eroded bone compared with the 'assessed bone volume', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2: 11-20% bone eroded; 3:21-30% of bone eroded; 4: 31-40% of bone eroded; 5: 51-60% bone eroded; 7:61-70% of bone eroded; 8: 71-80% of bone eroded; 9: 81-90% bone eroded; 10:\\>=91% of bone eroded.\n\nHigher score indicates worsening of erosion. Score ranges from 0 to 140.",
        "timeFrame": "Baseline, 12 months"
      }
    ],
    "secondary": [
      {
        "measure": "Decrease in Bone Reabsorption",
        "description": "Change in bone reabsorption as measured by serum carboxy-terminal collagen crosslinks (CTX) levels (pg/mL) over 12 months. Lower values represent varying degrees of suppression of normal bone turnover.\n\nThe reference ranges for C-terminal telopeptide in serum are as follows:\n\nFemale (premenopausal): 40-465 pg/mL Female (postmenopausal): 104-1008 pg/mL Male: 60-700 pg/mL",
        "timeFrame": "Baseline, 12 months"
      },
      {
        "measure": "Change in Subject Reported Functional Status (Disability)",
        "description": "Change in subject reported functional status (disability) by Health Assessment Questionnaire (HAQ) will be assessed from baseline over 12 months. 0 to 1 are generally considered to represent mild to moderate difficulty, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.",
        "timeFrame": "Baseline, 12 months"
      },
      {
        "measure": "Subject Reported Change in Physical Health",
        "description": "Subject reported change in physical and mental health by Short Form Health Survey (SF-12) scores assessed from baseline over 12 months. Range 0-100 with higher scores representing better self-reported health.",
        "timeFrame": "Baseline, 12 months"
      },
      {
        "measure": "Subject Reported Change in Mental Health",
        "description": "Subject Reported Change in Mental Health on SF-12 mental component form. Range 0-100 with higher scores representing better self-reported health",
        "timeFrame": "Baseline, 12 months"
      },
      {
        "measure": "Assessment of Pain",
        "description": "Assessment of pain score by visual analogue scale (VAS) reported from baseline over 12 months. Range 0-10 with higher scores representing more pain.",
        "timeFrame": "Baseline, 12 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 6
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 49,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:59.971Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}